Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
NBLX / Noble Midstream Partners LP 8-K (Current Report)

2018-07-03 sec.gov
Document UNITED STATES
NBLX

2
Noble Energy: DJ Basin Should Get More Attention

2018-07-02 seekingalpha
Minor non-core divestment aside, the DJ Basin remains one of Noble Energy's growth drivers as development activity ramps up.
NBLX NBL

2
NBLX / Noble Midstream Partners LP / Harvest Fund Advisors LLC - SC 13G/A (Passive Investment)

2018-06-08 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NBLX

2
NBLX / Noble Midstream Partners LP / Harvest Fund Advisors LLC - SC 13G/A (Passive Investment)

2018-06-08 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
NBLX

13
4 Top Energy Midstream MLPs Could Benefit From Issues in the Permian

2018-06-07 247wallst
For the longest time, it was the golden shale area of the United States. The Permian Basin in West Texas has delivered unprecedented production growth for domestic exploration and production companies, but it’s looking now that a great deal of Permian production could be constrained through 2020, a situation that one firm feels could cause some upstream companies misery, but for midstream companies, it could be an opportunity.
ETP.PRC ETP NBLX NBL SXL ETE PAA TRGP

2
Noble Energy: On A Roll

2018-06-05 seekingalpha
Noble Energy, Inc. reported adjusted earnings of 0.35 per share in the first quarter of 2018, beating the Zacks Consensus Estimate of 0.28.
NBLX NBL

2
Noble Midstream Partners (NBLX) Presents At MLP & Energy Infrastructure Conference - Slideshow

2018-05-23 seekingalpha
The following slide deck was published by Noble Midstream Partners LP in conjunction with this event.
NBLX

26
Noble Energy Finalizes Strategic Pipeline Agreement to Move Permian Crude Oil to Corpus Christi

2018-05-10 globenewswire
Houston, May 10, 2018 (GLOBE NEWSWIRE) -- Noble Energy, Inc. (NYSE: NBL) (“Noble Energy” or “the Company”) today announced that it has finalized an agreement with EPIC Pipeline, LP (“EPIC”) to transport crude oil from the Company’s Delaware Basin acreage position to Corpus Christi, Texas. Noble Energy has secured firm capacity for 100 thousand barrels of oil per day (MBbl/d) for a 10-year period beginning at pipeline start-up.
NBLX APA NBL

3
Noble Midstream Partners' (NBLX) CEO Terry Gerhart on Q1 2018 Results - Earnings Call Transcript

2018-05-01 seekingalpha
Noble Midstream Partners LP (NYSE:NBLX) Q1 2018 Earnings Conference Call May 1, 2018 2:00 PM ET
NBLX NBL BDIMF BDE BDI

2
Noble Energy (NBL) Q1 2018 Results - Earnings Call Transcript

2018-05-01 seekingalpha
Good morning and welcome to Noble Energy's First Quarter 2018 Earnings Results Webcast and Conference Call. Following today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded.
NBLX NBL ROSE

2
Noble Midstream Partners LP 2018 Q1 - Results - Earnings Call Slides

2018-05-01 seekingalpha
The following slide deck was published by Noble Midstream Partners LP in conjunction with their 2018 Q1 earnings call.
NBLX

22
Top MLP Gainers in the Week Ending April 27

2018-05-01 marketrealist
Navios Maritime Midstream Partners (NAP) is an MLP involved in the marine transportation of crude oil, refined products, and NGLs. Navios Maritime Midstream Partners was the top MLP gainer for the second consecutive in the week ending April 27. The partnership rallied 6.4% last week. The recent surge in Navios Maritime Midstream Partners’ stock price could be due to a rating upgrade by J.P. Morgan.
TOO APLP DCP ENLK MMLP NAP TOO.PRE NBLX CVRR SPH TOO.PRB TOO.PRA FGP

2
NBLX / Noble Midstream Partners LP 8-K (Current Report)

2018-05-01 sec.gov
Document UNITED STATES
NBLX

2
BRIEF-Noble Midstream Partners Increases Quarterly Distribution

2018-04-26 reuters
* NOBLE MIDSTREAM PARTNERS LP - BOARD OF CO’S GENERAL PARTNER DECLARED CASH DISTRIBUTION OF $0.5110/UNIT FOR Q1 2018, A 24% INCREASE VERSUS PRIOR YEAR QUARTER
NBLX

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

31m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

1h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 65506L105